Cholangitis, SclerosingNCT03146936
Swiss Primary Sclerosing Cholangitis Cohort Study
An observational study of Cholangitis, Sclerosing and PSC, run by Fondazione Epatocentro Ticino at 21 sites in Switzerland.
Trial summary
Research project in which biological material is sampled and health-related personal data is further used and collected. Coded data are used. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cholangitis, Sclerosing, PSC, Primary Sclerosing Cholangitis (PSC)
- How many people
- 120 participants
- Where
- 21 sitesSwitzerland
- Study dates
- 28 Feb 2017to 31 Dec 2030
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: PSC patients living in Switzerland of any age Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases). Only patients living in Switzerland are enrolled. Enrollment of minors is possible upon consent of legal guardian
Who may be able to join
- Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases) of any age. Patients not fulfilling such criteria but still diagnosed with PSC in a hepatology referral centre can be included
- patients living in Switzerland
Who cannot join
- N/A
Trial locations and contacts
21 sites in 1 country. Contact the study team or a site near you to ask about taking part.
21 sites in 1 country
Switzerland21 sites, 21 recruiting
- Recruiting
Gastroenterologie und Hepatologie Clarunis - Universitäres Bauchzentrum Universitätsspital Basel
Basel, 4031
Christine Bernsmeier, PD Dr. med. Dr. phil., +41 61 777 7400, Christine.Bernsmeier@clarunis.ch
- Recruiting
Universitäts-Kinderspital beider Basel UKBB, Gastroenterologie&Ernährung
Basel, 4031
Raoul Furlano, PD MD, +4161 704 12 13, raoul.furlano@ukbb.ch
- Recruiting
Inselspital
Bern, 3010
Maria Gabriela Delgado, MD, +4131 632 09 00, mariagabriela.delgado@insel.ch
- Recruiting
Kinderklinik, INSELSpital, Universität Bern, Pädiatrische Gastroenterologie, Hepatologie und Ernährung
Bern, 3010
Christiane Sokollik, MD, +4131 632 50 93, Christiane.Sokollik@insel.ch
- Recruiting
Spital Bülach
Bülach, 8180
Stephan Böhm, Prof. Dr. med, +41 44 863 24 30, stephan.boehm@spitalbuelach.ch
- Recruiting
Kantonsspital Graubünden
Chur, 7000
Simon Brunner, Dr. med., +41 81 256 63 07, simon.brunner@ksgr.ch
- Recruiting
Hôpitaux Universitaires de Genève, Centre Suisse des Maladies du foie de l'Enfant- Département de l'Enfant et de l'Adolescent
Geneva, 1205
Valérie McLin, Prof., +4122 382 45 72, Valerie.Mclin@hcug.ch
- Recruiting
Hôpitaux Universitaires de Genève, Service de Gastroentérologie & Hépatologie, Département des Spécialités
Geneva, 1205
Giulia Magini, Dr. med., +41 22 372 93 40, giulia.magini@hug.ch
- Recruiting
CHUV: Centre hospitalier universitaire vaudois
Lausanne, 1005
Montserrat Fraga Christinet, +41 21 314 04 33, montserrat.fraga@chuv.ch
- Recruiting
CHUV Département femme-mère-enfant
Lausanne, 1011
Andreas Nydegger, MD, +41 21 314 11 11, andreas.nydegger@chuv.ch
- Recruiting
Kantonsspital Baselland
Liestal, 4410
Magdalena Filipowicz-Sinnreich, MD, +41 61 925 23 60, Magdalena.Filipowicz@ksbl.ch
- Recruiting
Kinderspital Luzern LUKS, Pädiatrische Gastroenterologie
Lucerne, 6000
Franziska Righini-Grunder, Dr. med., +4141 205 32 09, franziska.righini@luks.ch
- Recruiting
Luzerner Kantonsspital
Lucerne, 6000
Andrea De Gottardi, Prof. Dr. med, +41 41 205 21 31, Andrea.DeGottardi@luks.ch
- Recruiting
Fondazione Epatocentro Ticino
Lugano, Canton Ticino, 6900
Andreas Cerny, Prof. Dr. med, +41 91 910 6570, andreas.cerny@hin.ch
- Recruiting
EOC Ospedale Regionale di Lugano - Italiano
Lugano, 6900
Benedetta Terziroli Beretta-Piccoli, MD, +41 91 811 7637, Benedetta.TerziroliBeretta-Piccoli@eoc.ch
- Recruiting
Ostschweizer Kinderspital
Sankt Gallen, 9006
Pascal Müller, MD, +4171 243 13 44, pascal.mueller@kispisg.ch
- Recruiting
Kantonsspital St.Gallen
Sankt Gallen, 9007
David Semela, MD, +4171 4941216, David.Semela@kssg.ch
- Recruiting
Kantonsspital Winterthur
Winterthur, 8400
Björn Becker, MD, +41 052 266 21 21, bjoern.becker@ksw.ch
- Recruiting
Pädiatrische Gastroenterologie Departement Kinder- und Jugendmedizin Kantonsspital Winterthur
Winterthur, 8400
Klaas Heyland, Dr. med., +41 522663452, klaas.heyland@ksw.ch
- Recruiting
Universitäts-Kinderspital Zürich - Eleonorenstiftung
Zurich, 8032
Carsten Posovszky, Prof. Dr. med, +41 44 249 60 41, carsten.posovszky@kispi.uzh.ch
- Recruiting
Universitätsspital Zürich
Zurich, 8091
Andreas Kremer, Prof. Dr. med, +41 44 255 85 48, andreas.kremer@usz.ch
About this study
Research project in which biological material is sampled and health-related personal data is further used and collected.
Coded data are used.
Read the detailed description
The investigators wish to collect high quality prospective data on a rare disease in order to elucidate epidemiology, natural history, response to treatment and outcome. In addition, a biobank allows addressing specific scientific issues on a variety of open questions. The cohort will provide a platform for carrying out scientific research projects on PSC. In addition, the cohort will allow collaborations with reference networks on PSC abroad
- Keywords
- PSC, Primary Sclerosing Cholangitis, Cohort
- Medical subject headings
- Cholangitis, Sclerosing
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease course
Observing disease course
Measured: 3 years
Disease features
Observing disease features in Swiss population and see if they are similar to other countries'
Measured: 3 years
Response to treatment
Observing response to treatment
Measured: 3 years
Overall survival
Observing overall survival
Measured: 3 years
Transplantation-free survival rate
Observing transplantation-free survival rate
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2017
- Study start28 Feb 2017
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cholangitis, SclerosingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Fondazione Epatocentro Ticino
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03146936
- Sponsor's protocol ID
- SASL40 - Swiss PSC Cohort
- Status last verified
- Aug 2025
- First submitted
- 8 May 2017
- Last updated
- 19 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Swiss Primary Sclerosing Cholangitis Cohort Study
- ClinicalTrials.gov ID
- NCT03146936
- Acronym / sponsor ID
- SASL40 - Swiss PSC Cohort
- Keywords
- PSC, Primary Sclerosing Cholangitis, Cohort
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Fondazione Epatocentro TicinoUniversity, hospital or other
- Study start
- 28 Feb 2017 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 10 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research project in which biological material is sampled and health-related personal data is further used and collected.
Coded data are used.
Detailed description
The investigators wish to collect high quality prospective data on a rare disease in order to elucidate epidemiology, natural history, response to treatment and outcome. In addition, a biobank allows addressing specific scientific issues on a variety of open questions. The cohort will provide a platform for carrying out scientific research projects on PSC. In addition, the cohort will allow collaborations with reference networks on PSC abroad
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- PSC patients living in Switzerland of any age Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases). Only patients living in Switzerland are enrolled. Enrollment of minors is possible upon consent of legal guardian
Key inclusion criteria (2 listed)
- Patients diagnosed with PSC according to established criteria (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases) of any age. Patients not fulfilling such criteria but still diagnosed with PSC in a hepatology referral centre can be included
- patients living in Switzerland
Key exclusion criteria (1 listed)
- N/A
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Disease course
Time frame: 3 years
Observing disease course
Disease features
Time frame: 3 years
Observing disease features in Swiss population and see if they are similar to other countries'
Response to treatment
Time frame: 3 years
Observing response to treatment
Overall survival
Time frame: 3 years
Observing overall survival
Transplantation-free survival rate
Time frame: 3 years
Observing transplantation-free survival rate
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Cholangitis, Sclerosing
Not yet recruitingPhase 2
FEAST and HOPE: Redox PSC Pilot Study
Primary Sclerosing Cholangitis (PSC)
Active, not recruitingPhase 2
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Primary Sclerosing Cholangitis
RecruitingPhase 3
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Active, not recruitingPhase 2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis
RecruitingObservational study
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Primary Sclerosing Cholangitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
21 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cholangitis, Sclerosing and PSC, run by Fondazione Epatocentro Ticino at 21 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 21 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andreas Cerny, Prof. Dr. med (+41 91 910 6570, andreas.cerny@hin.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease course (time frame: 3 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2025.